Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Trial ID or NCT#
The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.
Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)
- - Planned or completed first allogeneic stem cell transplant (any conditioning regimen, graft source, donor type and GVHD prophylaxis regimen) - Signed, informed consent and, if applicable, child assent
- - Inability to comply with study procedures - Anticipated survival less than 6 months due to co-morbid disease - Autoimmune disorder or inherited immunodeficiency before HCT - Diagnosis of late acute or chronic GVHD prior to study enrollment - Hematologic relapse or chemotherapy refractory disease at restaging within 1 month of HCT or at the time of enrollment (e.g., > 5% blasts for leukemia; poorly responsive lymphoma)
Contact us to find out if this trial is right for you.